Featured Press Releases

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

LenioBio partners with ReciBioPharm to scale up ALiCE® technology and accelerate vaccine production

LenioBio partners with ReciBioPharm to scale up ALiCE® technology and accelerate vaccine production

  • 02 Oct 2024

LenioBio, the leader in rapid cell-free protein expression technologies, is pleased to announce a...

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

SeoulTech researchers unveil a novel approach to understanding PFOS-induced neurotoxicity, advancing environmental health studies

SeoulTech researchers unveil a novel approach to understanding PFOS-induced neurotoxicity, advancing environmental health studies

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

SK bioscience Improves Vaccine Access by Securing Its First UNICEF Procurement Contract

SK bioscience Improves Vaccine Access by Securing Its First UNICEF Procurement Contract

ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

  • ImmunoScape Pte. Ltd.
  • 23 Sep 2026
LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

  • LEVEL
  • 22 Sep 2026
FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

  • Merck & Co., Inc.
  • 22 Sep 2026
Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

  • Padagis
  • 21 Sep 2026
StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

  • StimCardio’s
  • 21 Sep 2026
Bruker Receives Order for High-Field NMR Systems to Support a Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley.

Bruker Receives Order for High-Field NMR Systems to Support a Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley.

  • Bruker Corporation
  • 21 Sep 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.